Biohaven BHV-1530 data selected for oral presentation
Biohaven said clinical data on BHV-1530, a novel FGFR3-directed ADC with a proprietary TopoIx payload, was selected for oral presentation at the EORTC-NCI-AACR Symposium 2026.
Biohaven said clinical data on BHV-1530, a novel FGFR3-directed ADC with a proprietary TopoIx payload, was selected for oral presentation at the EORTC-NCI-AACR Symposium 2026.